Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
iRhythm Technologies, a leader in digital health care, announced its participation in the 42nd Annual William Blair Growth Stock Conference. The presentation is scheduled for June 8, 2022, at 2:40 p.m. Central Time. Interested parties can access the live and archived webcast via the company’s website.
iRhythm specializes in innovative cardiac care solutions, using wearable biosensor devices and advanced data analytics to improve the diagnosis of cardiac arrhythmias.
iRhythm Technologies reported strong first-quarter results for 2022, with revenue reaching $92.4 million, a 24.3% increase year-over-year. Gross margin improved to 66.9%, despite a slight decline from last year. However, the company reported a net loss of $50.6 million, an increase from $27.8 million in Q1 2021, attributed to higher operating expenses driven by one-time charges. Looking ahead, iRhythm projects 2022 revenue between $410 million and $420 million, anticipating growth of 27% to 30% compared to 2021.
iRhythm Technologies (NASDAQ: IRTC) announced the appointment of Dr. Mintu Turakhia as Chief Medical Officer and Chief Scientific Officer, aiming to enhance its innovation and clinical product portfolio. Dr. Turakhia is renowned for his work in cardiac care and digital health, with over 20 years of experience. His leadership is expected to drive advancements in the company’s technology and services. Additionally, Chief Clinical Officer Judy Lenane will retire after 14 years, with the company recognizing her significant contributions to its success.
iRhythm Technologies (NASDAQ: IRTC) will announce its first-quarter 2022 financial results after trading closes on May 5, 2022. The management team will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. iRhythm specializes in cardiac care through its innovative wearable biosensor devices and cloud-based analytics, which aim to enhance arrhythmia detection and management. Interested investors can access the live and archived call via the company’s website.
iRhythm Technologies (NASDAQ: IRTC) presented promising clinical research at ACC.22, highlighting the effectiveness of its Zio service for early detection of silent atrial fibrillation (AF). Key findings include:
- Zio AT reduced hospital resources, saving a healthcare system 136 inpatient days.
- 4.5% of high-risk patients using Zio XT were diagnosed with AF within two weeks.
- Post-TAVR monitoring with Zio AT revealed a significant incidence of arrhythmias, notably AF in 25% of patients.
This data underscores Zio’s role in improving patient care and hospital workflows, particularly amidst ongoing healthcare challenges.
iRhythm Technologies announced an amended credit facility with Silicon Valley Bank, enhancing its borrowing capacity to $100 million. This includes a term loan of $75 million and a revolving credit line of $25 million, maturing on March 1, 2027. The company has drawn down $35 million to pay off previous debt and fund working capital. This non-dilutive financing strengthens iRhythm's financial position, supporting growth in cardiac care through advanced monitoring solutions.
iRhythm Technologies, Inc. (NASDAQ: IRTC) announced the retirement of Kevin King from its Board of Directors, effective April 1, 2022. King joined the Board in July 2012 and previously led the company as President and CEO until January 2021. His leadership was pivotal in iRhythm's growth and success in cardiac care, where it has served over four million patients. Quentin Blackford, current President and CEO, expressed gratitude for King's contributions, highlighting his role in establishing the company as a leader in cardiac monitoring technology.
iRhythm Technologies (NASDAQ: IRTC) announced positive findings from the KP-Rhythm2 study, confirming that its Zio XT cardiac monitoring patch effectively detects bradyarrhythmias in patients undergoing transcatheter aortic valve replacement (TAVR).
The study shows Zio XT significantly outperforms Holter and event monitors in diagnosing arrhythmias, leading to more timely interventions and reduced healthcare costs.
iRhythm Technologies reported its Q4 and full-year 2021 financial results, showing a 3.8% increase in revenue to $81.8 million for Q4, while full-year revenue rose 21.7% to $322.8 million. However, gross margins declined to 62.7% in Q4 and 66.2% for the year due to lower Zio XT reimbursement rates and rising costs. The company posted a Q4 net loss of $32.5 million and a full-year net loss of $101.4 million. For 2022, iRhythm projects revenue growth of 24% to 27% and expects adjusted EBITDA to remain negative, ranging from negative $30 to $40 million.
Galderma, the largest independent dermatology company, announced the appointment of Karen L. Ling to its Advisory Committee, effective March 1, 2022. Ms. Ling brings over 25 years of global human resources experience from executive positions at AIG, Allergan, Merck, and Wyeth, focusing on talent management and organizational culture. Currently, she serves on the Boards of iRhythm Technologies (NASDAQ: IRTC) and TherapeuticsMD (NASDAQ: TXMD). Both Thomas Ebeling and Flemming Ørnskov expressed enthusiasm about her joining, highlighting her strengths in human capital management and diversity initiatives.